Ahead of its time, a GLP-1 drug almost made it out of India

Fifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes management and weight loss. Unfortunately, due to prohibitive clinical trial costs and a skeptical outlook on the obesity market, Zydus chose to shelve further development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bFBIjhY
via IFTTT

Read More

Child hears again 18 months after brain stem implant at AIIMS

A young boy in India has received a groundbreaking auditory brain stem implant. This marks a first for AIIMS. The surgery was performed after conventional implants were not suitable. The child is now responding to sounds and speaking more clearly. Doctors highlight the importance of early detection for hearing loss.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DiS2nva
via IFTTT

Read More

NATCO Pharma launches generic blood cancer treatment medicine in US

NATCO Pharma has launched generic Pomalidomide capsules in the US. This drug treats blood and bone marrow cancer. It is a generic version of Celgene's Pomalyst. The launch is in partnership with Breckenridge Pharmaceutical. This move aims to make specialty medicines accessible. It offers an affordable solution for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/845bQ6z
via IFTTT

Read More

Eli Lilly sticks to premium pricing for its innovator drug ahead of generics wave

Eli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite its premium pricing, even as lower-cost semaglutide generics prepare to enter the Indian market.Winselow Tucker, president and general manager of Eli Lilly and Company (India), told ET that the company sees room for both branded innovator drugs and generics to thrive simultaneously in the rapidly expanding domestic segment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ks8Hj03
via IFTTT

Read More

All our AI models have scientists in loop, says MSD chief AI officer

MSD's Chief AI Officer, Anton Groom, highlights AI's transformative role in drug discovery. AI models like TEDDY and KERMT are assisting scientists, identifying new drug targets and refining lead identification. This technology is accelerating the development of new medicines, with two AI-discovered molecules already in clinical trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/utByhpW
via IFTTT

Read More

Brain can keep producing new neurons in old age, but Alzheimer’s may disrupt the process: Study

New research reveals the adult brain generates fresh nerve cells in the hippocampus, vital for memory. This ability declines in Alzheimer's patients. Scientists observed this process in postmortem brain samples. Healthy older adults show continued neuron production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CarbWi1
via IFTTT

Read More

ACC clears Dr Rajeev Singh Raghuvanshi’s reappointment as Drugs Controller (India)

Dr Rajeev Singh Raghuvanshi will continue as Drugs Controller (India) at CDSCO. His reappointment is on a contract basis for one year starting March 1, 2026. This decision follows a proposal from the Department of Health and Family Welfare. Dr Raghuvanshi heads the CDSCO, responsible for drug quality and new drug approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8FeGzSH
via IFTTT

Read More